This presentation provides an overview of the FDA’s Expanded Access Program, which permits pre-approval access to drugs in development.  The discussion will address the following:

•   Basic information and definitions for expanded access
•   Review of expanded access categories
•   Required FDA forms for expanded access submissions

Submit advance questions or comments to o3is@pitt.edu.